← SynDRA

ACRIVASTINE

SynDRA canonical compound SYN0004722 — structure-anchored drug synonym record

All known targets

• HRH1
• ABCB1

Mechanisms of action (all sources)

• HRH1 ANTAGONIST
• Histamine H1 receptor antagonist
• histamine receptor antagonist

Drug classes

• Histamine H1 Receptor Antagonists
• Histamine-1 Receptor Antagonist
• Histamine Agents
• Histamine Antagonists
• Histamine H1 Antagonists
• Histamine H1 Antagonists, Non-Sedating
• Neurotransmitter Agents

ATC classes

• R06A · ANTIHISTAMINES FOR SYSTEMIC USE

Cross-references

• PubChem CID: 5284514
• ChEMBL: CHEMBL1224
• DrugBank: DB09488
• ChEBI: CHEBI:83168
• KEGG: D02760
• Wikipedia: Acrivastine
• TTD: D0O4EU

Synonyms

• BW-270C
• BW-825C
• semprex
• Acrivastina
• Acrivastine component of semprex-d
• Benadryl allgy relief plus decongest
• Semprex
• Acrivastin
• Acrivastinum
• Acrivastina [Spanish]
• Acrivastinum [Latin]
• Benadryl allergy relief
• BW 0270C
• BW A825C
• Acrivastine (USAN/INN)
• Acrivastine [USAN:INN:BAN]
• E-(9CI)
• (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
• (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid
• (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid
• (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure
• (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid
• 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
• BW 825C
• A20F9XAI7W
• CHEBI:83168
• DTXCID702555
• Benadryl Allgy Relief Plus Decongest
• BW825C
• RefChem:552703
• R06AX18
• MFCD00869830
• NCGC00182053-02
• UNII-A20F9XAI7W
• Acrivastine (Standard)
• ACRIVASTINE [MI]
• ACRIVASTINE [INN]
• ACRIVASTINE [USAN]

Reported adverse events

• Dizziness
• Somnolence
• Asthenia
• Cough
• Dyspepsia
• Headache
• Insomnia
• Nausea
• Nervousness
• Pharyngitis